Clinical Trial Update: Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib in combination with dose-dense temozolomide for first recurrent/progressive glioblastoma after STUPP regimen.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Anlotinib (anlotinib)
• temozolomide (dose-dense) (temozolomide)

Snippet

Sponsor: Yonggao Mou | Conditions: Glioblastoma | Phase 2 | Status: UNKNOWN